Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.14
−$0.09 · -2.13%
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Previous close
$4.14
−$0.09 · -2.13%
After-hours
$4.14
$0.00 · 0.00%
Sep 16, 7:30 PM ET
Regular session · ET · Market data may be delayed.
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Day range
Current $4.14
52-week range
Current $4.14
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
58
Fair Value
Sentiment
63
Bullish
Risk
71
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Day range
Current $4.14
52-week range
Current $4.14
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 19.09M USD | — | — | 15M USD | — |
| Cost of goods sold | 705K USD | 58K USD | — | — | 734K USD |
| Gross profit | 18.38M USD | −58K USD | — | 15M USD | −734K USD |
| Research and development | 18.67M USD | 29.8M USD | 59.5M USD | 21.13M USD | 37.93M USD |
| Selling, general, and administrative | 90.85M USD | 28.75M USD | 12.93M USD | 4.36M USD | 21.78M USD |
| Operating expenses | 109.52M USD | 58.55M USD | 72.43M USD | 25.48M USD | 59.71M USD |
| Interest income | 9.76M USD | 8.55M USD | 2.19M USD | — | — |
| Depreciation and amortization | 287K USD | 58K USD | 15K USD | 8K USD | 734K USD |
| Operating income | −91.14M USD | −58.61M USD | −72.43M USD | −10.48M USD | −60.44M USD |
| Net income | −82.13M USD | −49.77M USD | −69.97M USD | −10.81M USD | −70.76M USD |
Company facts updated Sep 17, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.00
69.08% upside| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Mar 22, 2024 | $1.03Weekly | Mar 18, 2024 | — |
Dividend | Mar 15, 2024 | $1.03Weekly | — | — |
Ex-dividend Mar 22, 2024
$1.03
Weekly
Record Mar 18, 2024
Ex-dividend Mar 15, 2024
$1.03
Weekly
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.27M0.00%2.3T USD0.03%$371.26-0.42%
iShares Russell 2000 ETFIWM2.31M0.00%79.89B USD0.19%$283.92-0.43%
Vanguard Extended Market ETFVXF1.32M0.00%95.4B USD0.05%$234.39-0.32%
Fidelity Enhanced Small Cap ETFFESM1.01M0.02%6.49B USD0.28%$45.80-0.20%
iShares Biotechnology ETFIBB877.11K0.01%10.45B USD0.44%$202.4+0.20%
iShares Russell 2000 Value ETFIWN725.45K0.01%14.31B USD0.24%$215.86-0.84%
Vanguard Russell 2000 ETFVTWO615.25K0.00%18B USD0.06%$115.07-0.43%
Schwab U.S. Small-Cap ETFSCHA437.65K0.00%22.03B USD0.03%$33.06-0.29%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
